CDNA's Quality Score rose 3 points on Fri, Oct 30, to 24. Buying volume reached a 20-day high (3 chart checks started).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 22% on Oct 30 while the S&P 500 fell 2%.
“Adjusted EBITDA was $30 million, compared with $15 million in the third quarter of 2025, driven by revenue growth”
| Buybacks | 5.2% fewer shares than a year ago |
| Its score | Up:Highest Quality Score since at least Oct 2021 |
| Latest filing | 8-K, Oct 29 |
ReportThu Oct 29: sales of $139.4M; a profit of $0.35 a share. Raised its outlook for the year. Past reports ›
Fri Oct 30CareDx reported quarterly revenue of $139.4 million and diluted EPS of $0.35
After its last 4 reports it closed +6.9% on average, higher 2 of 4 times.
Exceptionalfor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. CDNA scores 24 today, against a median of 16 over its last 20 recorded sessions.
CDNA is #1 of 17 by Quality Score among Services-Medical Laboratories.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score |
Share count against a year before: CDNA -5.2%, GRAL +20%, DGX -0.9%.
Expected to report Wed Feb 24, after the close (in 114 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $139.4M, 39% more than a year ago; a profit of $0.35 a share, from $0.03.
“Total revenue was $139 million, compared with $100 million in the third quarter of 2025, an increase of 39% year-over-year, driven primarily by growth in Testing Services and Patient and Digital Solutions revenue, including the addition of Specialty Oncology revenue following our acquisition of NavDx.”
CDNA's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Revenue | $520M to $530M |
“Adjusted EBITDA was $30 million, compared with $15 million in the third quarter of 2025, driven by revenue growth, higher gross profit and disciplined operating expense management.”
From its results filing (SEC filing · Oct 29)
Sales grew 15% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 2.8% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 29, 2026 | +12.7% | +22.2% | open |
| Jul 30, 2026 | +11.5% | +14.7% | +17.6% |
| Apr 28, 2026 | +2.1% | -5.1% | -5.5% |
Sales grew in six of the last seven years, to $380M in 2025. It lost money in 2025 after a profit in 2024.
3 insiders sold $3.2M across 4 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: CDNA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
“With our comprehensive portfolio of surveillance testing services, diagnostic products and patient and digital solutions business offerings, we face different types of competition.”
CDNA scores 24 today, which Breakaway calls Exceptional. It is #1 of 17 in Services-Medical Laboratories by Quality Score, with 8 of 14 chart checks firing. Up 22% on Oct 30 while the S&P 500 fell 2%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
CDNA scores 24 today, which Breakaway calls Exceptional (20 or more). That is #1 of 17 in Services-Medical Laboratories by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CDNA's 24.
3 insiders sold $3.2M across 4 filings in the last 6 months. No open-market buys on record. The newest is Michael Goldberg, Director, who sold $2.1M on Aug 4. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.